SciSparc 6-K notes Israeli patent move on depression treatment

Rhea-AI Filing Summary

SciSparc Ltd. (SPRC) filed a Form 6-K noting that it has furnished a press release dated November 20, 2025. The release announces that Neurothera Labs submitted an Israeli patent application in collaboration with Clearmind Medicine for a novel non-hallucinogenic neuroplastogen treatment for depression. The filing also states that this Form 6-K is incorporated by reference into several of SciSparc’s existing shelf and employee equity registration statements, meaning the information becomes part of those previously filed offerings.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2025 (Report No. 2)

Commission File Number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

On November 20, 2025, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K and is incorporated by reference herein.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-233417, 333-248670 and 333-255408) and on Form S-8 (File Nos. 333-278437, 333-225773 and 333-286791) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release issued by SciSparc Ltd. titled “SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SciSparc Ltd.
Date: November 20, 2025	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

3

FAQ

What did SciSparc Ltd. (SPRC) report in this Form 6-K?

SciSparc reported that it furnished a press release announcing an Israeli patent application by Neurothera Labs, in collaboration with Clearmind Medicine, for a non-hallucinogenic neuroplastogen treatment for depression.

What is the main scientific focus mentioned by SciSparc (SPRC) in this filing?

The focus is a novel non-hallucinogenic neuroplastogen treatment for depression, tied to an Israeli patent application submitted by Neurothera Labs with Clearmind Medicine.

Does this SciSparc (SPRC) Form 6-K involve new securities being offered?

The Form 6-K does not describe a new securities offering; it mainly furnishes a press release and incorporates the report into existing Form F-3 and Form S-8 registration statements.

How is this Form 6-K used in SciSparc’s (SPRC) existing registration statements?

The report is incorporated by reference into SciSparc’s Form F-3 and Form S-8 registration statements, making the information in this Form 6-K part of those filings from its submission date.

Which companies are named as collaborators in the patent application mentioned by SciSparc (SPRC)?

The patent application is associated with Neurothera Labs and is described as being in collaboration with Clearmind Medicine.

Does the SciSparc (SPRC) Form 6-K provide financial results or earnings data?

No, this Form 6-K does not provide financial or earnings data; it is focused on the furnished press release about the patent application.